<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Brice, A.</title>
    <link>http://repub.eur.nl/res/aut/52905/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy (Article)</title>
      <link>http://repub.eur.nl/res/pub/34193/</link>
      <pubDate>2011-07-01T00:00:00Z</pubDate>
      <description>Progressive supranuclear palsy (PSP) is a movement disorder with prominent tau neuropathology. Brain diseases with abnormal tau deposits are called tauopathies, the most common of which is Alzheimer's disease. Environmental causes of tauopathies include repetitive head trauma associated with some sports. To identify common genetic variation contributing to risk for tauopathies, we carried out a genome-wide association study of 1,114 individuals with PSP (cases) and 3,247 controls (stage 1) followed by a second stage in which we genotyped 1,051 cases and 3,560 controls for the stage 1 SNPs that yielded P ≤ 10-3. We found significant previously unidentified signals (P &lt; 5 × 10-8) associated with PSP risk at STX6, EIF2AK3 and MOBP. We confirmed two independent variants in MAPT affecting risk for PSP, one of which influences MAPT brain expression. The genes implicated encode proteins for vesicle-membrane fusion at the Golgi-endosomal interface, for the endoplasmic reticulum unfolded protein response and for a myelin structural component. </description>
    </item> <item>
      <title>Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/34220/</link>
      <pubDate>2011-05-01T00:00:00Z</pubDate>
      <description>We sought to identify new susceptibility loci for Alzheimer's disease through a staged association study (GERAD+) and by testing suggestive loci reported by the Alzheimer's Disease Genetic Consortium (ADGC) in a companion paper. We undertook a combined analysis of four genome-wide association datasets (stage 1) and identified ten newly associated variants with P ĝ‰Currency sign 1 × 10-5. We tested these variants for association in an independent sample (stage 2). Three SNPs at two loci replicated and showed evidence for association in a further sample (stage 3). Meta-analyses of all data provided compelling evidence that ABCA7 (rs3764650, meta P = 4.5 × 10-17; including ADGC data, meta P = 5.0 × 10-21) and the MS4A gene cluster (rs610932, meta P = 1.8 × 10-14; including ADGC data, meta P = 1.2 × 10-16) are new Alzheimer's disease susceptibility loci. We also found independent evidence for association for three loci reported by the ADGC, which, when combined, showed genome-wide significance: CD2AP (GERAD+, P = 8.0 × 10-4; including ADGC data, meta P = 8.6 × 10-9), CD33 (GERAD+, P = 2.2 × 10-4; including ADGC data, meta P = 1.6 × 10-9) and EPHA1 (GERAD+, P = 3.4 × 10-4; including ADGC data, meta P = 6.0 × 10-10). </description>
    </item>
  </channel>
</rss>